328 related articles for article (PubMed ID: 35126843)
1. Is there a role of lipid-lowering therapies in the management of fatty liver disease?
Tzanaki I; Agouridis AP; Kostapanos MS
World J Hepatol; 2022 Jan; 14(1):119-139. PubMed ID: 35126843
[TBL] [Abstract][Full Text] [Related]
2. Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.
Ahsan F; Oliveri F; Goud HK; Mehkari Z; Mohammed L; Javed M; Althwanay A; Rutkofsky IH
Cureus; 2020 Sep; 12(9):e10446. PubMed ID: 33072455
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
5. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
6. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Sahebkar A; Chew GT; Watts GF
Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
[TBL] [Abstract][Full Text] [Related]
7. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.
Nseir W; Mograbi J; Ghali M
Dig Dis Sci; 2012 Jul; 57(7):1773-81. PubMed ID: 22419057
[TBL] [Abstract][Full Text] [Related]
8. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?
Musso G; Anty R; Petta S
Curr Pharm Des; 2013; 19(29):5297-313. PubMed ID: 23394094
[TBL] [Abstract][Full Text] [Related]
9. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
10. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
11. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
12. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
Sfikas G; Psallas M; Koumaras C; Imprialos K; Perdikakis E; Doumas M; Giouleme O; Karagiannis A; Athyros VG
Curr Vasc Pharmacol; 2021; 19(5):572-581. PubMed ID: 33059580
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
Tacke F; Weiskirchen R
Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
[TBL] [Abstract][Full Text] [Related]
16. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.
Siddiqui MS; Fuchs M; Idowu MO; Luketic VA; Boyett S; Sargeant C; Stravitz RT; Puri P; Matherly S; Sterling RK; Contos M; Sanyal AJ
Clin Gastroenterol Hepatol; 2015 May; 13(5):1000-8.e3. PubMed ID: 25311381
[TBL] [Abstract][Full Text] [Related]
17. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
Le TA; Loomba R
J Clin Exp Hepatol; 2012 Jun; 2(2):156-73. PubMed ID: 25755424
[TBL] [Abstract][Full Text] [Related]
18. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
19. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.
Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H
Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]